Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis

British Journal of Cancer

Volumn 113, Issue 6, 2015, Pages 963-969

  Kirschner, Michaela B ^a,b,l   Pulford, Emily ^c   Hoda, Mir Alireza ^d   Rozsas, Anita ^d   Griggs, Kim ^c   Cheng, Yuen Yee ^a   Edelman, J James B ^e   Kao, Steven C ^a,f   Hyland, Rebecca ^a   Dong, Yawen ^d   László, Viktoria ^d   Klikovits, Thomas ^d   Vallely, Michael P ^b,e,g   Grusch, Michael ^h   Hegedus, Balazs ^d,i   Dome, Balazs ^d,j,k   Klepetko, Walter ^d   Van Zandwijk, Nico ^a,b   Klebe, Sonja ^c   Reid, Glen ^a,b  

^a Asbestos Diseases Research Institute   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f The Chris O Brien Lifehouse   (Australia)

^g MACQUARIE UNIVERSITY   (Australia)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^j NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^k SEMMELWEIS UNIVERSITY   (Hungary)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBULIN; FIBULIN 3; UNCLASSIFIED DRUG; EFEMP1 PROTEIN, HUMAN; SCLEROPROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELLULAR SECRETION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MESOTHELIUM CELL; MOUSE; NONHUMAN; PLEURA EFFUSION; PLEURA FLUID; PLEURA MESOTHELIOMA; PLEURA PLAQUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR XENOGRAFT; AGED; ANIMAL; CASE CONTROL STUDY; MESOTHELIOMA; METABOLISM; MIDDLE AGED; NUDE MOUSE; PLEURAL NEOPLASMS; PROGNOSIS; VERY ELDERLY; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HETEROGRAFTS; HUMANS; MALE; MESOTHELIOMA; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM PROTEINS; PLEURAL EFFUSION; PLEURAL NEOPLASMS; PROGNOSIS;

EID: 84941881227     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.286     Document Type: Article

References (44)

1. Agha MA, El-Habashy MM, El-Shazly RA (2014) Role of fibulin-3 in the diagnosis of malignant mesothelioma. Egypt J Chest Dis Tuberc 63(1): 99-105.
2. Albig AR, Neil JR, Schiemann WP (2006) Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 66(5): 2621-2629.
3. Altomare DA, You H, Xiao G-H, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR (2005) Human and mouse mesotheliomas exhibit elevated AKT//PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24(40): 6080-6089.
4. Argraves WS, Greene LM, Cooley MA, Gallagher WM (2003) Fibulins: physiological and disease perspectives. EMBO Rep 4(12): 1127-1131.
5. Camaj P, Seeliger H, Ischenko I, Krebs S, Blum H, De Toni EN, Faktorova D, Jauch KW, Bruns CJ (2009) EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem 390(12): 1293-1302.
6. Chen X, Meng J, Yue W, Yu J, Yang J, Yao Z, Zhang L (2014) Fibulin-3 suppresses Wnt/beta-catenin signaling and lung cancer invasion. Carcinogenesis 35(8): 1707-1716.
7. Corradi M, Goldoni M, Alinovi R, Tiseo M, Ampollini L, Bonini S, Carbognani P, Casalini A, Mutti A (2013) YKL-40 and Mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. Anticancer Res 33(12): 5517-5524.
8. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YCG, Skates SJ, Nowak AK, Robinson BWS (2014) Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 69(10): 895-902.
9. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S, Roncalli M (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51(2): 207-215.
10. Edwards JG, Swinson DE, Jones JL, Waller DA, O'Byrne KJ (2006) EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54(3): 399-407.
11. En-lin S, Sheng-guo C, Hua-qiao W (2010) The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol 117(3): 417-422.
12. Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, Abdel-Hamid A, Eldin NA, Mokhtar N (2010) Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 70(1): 43-50.
13. Gallagher WM, Currid CA, Whelan LC (2005) Fibulins and cancer: friend or foe? Trends Mol Med 11(7): 336-340.
14. Giltay R, Timpl R, Kostka G (1999) Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. Matrix Biol 18(5): 469-480.
15. Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Morley A, White P, Rahman NM, De Winton E, Clive A, Masani V, Arnold DT, Dangoor A, Guglani S, Jankowska P, Lowndes SA, Harvey JE, Braybrooke JP, Maskell NA (2015) The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br J Cancer 112(7): 1175-1182.
16. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, Mora ME, Nuovo GJ, Cole SE, Viapiano MS (2012) Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res 72(15): 3873-3885.
17. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS (2009) Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 7(11): 1756-1770.
18. Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A, Mathews MS, Ro DI, Alkafeef S, Hsu N, Hamamura M, Yu L, Hess KR, Tromberg BJ, Linskey ME, Zhou YH (2011) EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer 10: 123.
19. Hu YJ, Vo C, Li ZZ, Ke C, Ru N, Hess KR, Linskey ME, Zhou YH (2013) Efemp1 attenuates Egfr signaling activities and the prognostic effect of Efemp1depends on the level of Egfr expression in gliomas. Neuro Oncol 15: 18-18.
20. Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, Churg A, Dacic S, Fraire A, Galateau-Salle F, Gibbs A, Gown A, Hammar S, Litzky L, Marchevsky AM, Nicholson AG, Roggli V, Travis WD, Wick M (2013) Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 137(5): 647-667.
21. Hwang CF, Chien CY, Huang SC, Yin YF, Huang CC, Fang FM, Tsai HT, Su LJ, Chen CH (2010) Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol 222(4): 367-379.
22. Kim EJ, Lee SY, Woo MK, Choi SI, Kim TR, Kim MJ, Kim KC, Cho EW, Kim IG (2012) Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol 40(2): 402-408.
23. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY, Kim WJ (2011) EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 17(13): 4523-4530.
24. Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B (2004) Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1): implications for macular degenerations. J Biol Chem 279(29): 30469-30473.
25. Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmuller S, Karnthaler-Benbakka C, Kowol CR, Berger W, Heffeter P (2013) Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther 12(6): 1073-1084.
26. LaDou J, Castleman B, Frank A, Gochfeld M, Greenberg M, Huff J, Joshi TK, Landrigan PJ, Lemen R, Myers J, Soffritti M, Soskolne CL, Takahashi K, Teitelbaum D, Terracini B, Watterson A (2010) The case for a global ban on asbestos. Environ Health Perspect 118(7): 897-901.
27. Linton A, Cheng YY, Griggs K, Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC, Klebe S, van Zandwijk N, Reid G (2014) An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. Br J Cancer 110(2): 510-519.
28. Luo R, Zhang M, Liu L, Lu S, Zhang CZ, Yun J (2013) Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PloS one 8(8): e70511.
29. Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, Sugimoto H, Takeda S, Nakao A (2010) Epidermal growth factorcontaining fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 17(3): 923-932.
30. Olsen NJ, Franklin PJ, Reid A, de Klerk NH, Threlfall TJ, Shilkin K, Musk B (2011) Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 195(5): 271-274.
31. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367(15): 1417-1427.
32. Relan V, Morrison L, Parsonson K, Clarke BE, Duhig EE, Windsor MN, Matar KS, Naidoo R, Passmore L, McCaul E, Courtney D, Yang IA, Fong KM, Bowman RV (2013) Phenotypes and karyotypes of human malignant mesothelioma cell lines. PloS One 8(3): e58132.
33. Rena O, Boldorini LR, Gaudino E, Casadio C (2011) Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J Surg Oncol 104(6): 701-705.
34. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, Hellebrand H, Engert S, Seitz S, Kreutzfeld R, Sasaki T, Arnold N, Schmutzler R, Kiechle M, Niederacher D, Harbeck N, Dahl E, Meindl A (2009) Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 124(7): 1727-1735.
35. Schmitter D, Lauber B, Fagg B, Stahel RA (1992) Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 51(2): 296-301.
36. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, Thieme SE, Blum H, Assmann G, Jauch KW, Bruns CJ (2009) EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 7(2): 189-198.
37. Song EL, Hou YP, Yu SP, Chen SG, Huang JT, Luo T, Kong LP, Xu J, Wang HQ (2011) EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol 121(1): 174-180.
38. Timpl R, Sasaki T, Kostka G, Chu ML (2003) Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 4(6): 479-489.
39. Tong JD, Jiao NL, Wang YX, Zhang YW, Han F (2011) Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma 58(5): 441-448.
40. Wang R, Zhang YW, Chen LB (2010) Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer 69(2): 239-244.
41. Wu YJ, Parker LM, Binder NE, Beckett MA, Sinard JH, Griffiths CT, Rheinwald JG (1982) The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell 31(3 Pt 2): 693-703.
42. Yue W, Dacic S, Sun Q, Landreneau R, Guo M, Zhou W, Siegfried JM, Yu J, Zhang L (2007) Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 13(15 Pt 1): 4336-4344.
43. Zhang Y, Marmorstein LY (2010) Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res 90(3): 374-375.
44. Zhou YH (2013) EFEMP1 (EGF containing fibulin-like extracellular matrix protein 1). Atlas Genet Cytogenet Oncol Haematol 17(2): 115-120.